These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 17536108)

  • 21. Quantitative and qualitative analysis of [(18)F]FDG and [(18)F]FAZA positron emission tomography of head and neck cancers and associations with HPV status and treatment outcome.
    Graves EE; Hicks RJ; Binns D; Bressel M; Le QT; Peters L; Young RJ; Rischin D
    Eur J Nucl Med Mol Imaging; 2016 Apr; 43(4):617-25. PubMed ID: 26577940
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Can hypoxia-PET map hypoxic cell density heterogeneity accurately in an animal tumor model at a clinically obtainable image contrast?
    Busk M; Horsman MR; Jakobsen S; Hansen KV; Bussink J; van der Kogel A; Overgaard J
    Radiother Oncol; 2009 Sep; 92(3):429-36. PubMed ID: 19729214
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02.
    Rischin D; Hicks RJ; Fisher R; Binns D; Corry J; Porceddu S; Peters LJ;
    J Clin Oncol; 2006 May; 24(13):2098-104. PubMed ID: 16648512
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intratumoral spatial distribution of hypoxia and angiogenesis assessed by 18F-FAZA and 125I-Gluco-RGD autoradiography.
    Picchio M; Beck R; Haubner R; Seidl S; Machulla HJ; Johnson TD; Wester HJ; Reischl G; Schwaiger M; Piert M
    J Nucl Med; 2008 Apr; 49(4):597-605. PubMed ID: 18344437
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PET imaging of tumor hypoxia using 18F-labeled pimonidazole.
    Busk M; Jakobsen S; Horsman MR; Mortensen LS; Iversen AB; Overgaard J; Nordsmark M; Ji X; Lee DY; Raleigh JR
    Acta Oncol; 2013 Oct; 52(7):1300-7. PubMed ID: 23962243
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of three
    Dos Santos SN; Wuest M; Jans HS; Woodfield J; Nario AP; Krys D; Dufour J; Glubrecht D; Bergman C; Bernardes ES; Wuest F
    Nucl Med Biol; 2023; 124-125():108383. PubMed ID: 37651917
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hypoxic sensitizer and cytotoxin for head and neck cancer.
    Lee DJ; Moini M; Giuliano J; Westra WH
    Ann Acad Med Singap; 1996 May; 25(3):397-404. PubMed ID: 8876907
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Significant impact of different oxygen breathing conditions on noninvasive in vivo tumor-hypoxia imaging using [¹⁸F]-fluoro-azomycinarabino-furanoside ([¹⁸F]FAZA).
    Maier FC; Kneilling M; Reischl G; Cay F; Bukala D; Schmid A; Judenhofer MS; Röcken M; Machulla HJ; Pichler BJ
    Radiat Oncol; 2011 Nov; 6():165. PubMed ID: 22118419
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 18F-FAZA PET imaging response tracks the reoxygenation of tumors in mice upon treatment with the mitochondrial complex I inhibitor BAY 87-2243.
    Chang E; Liu H; Unterschemmann K; Ellinghaus P; Liu S; Gekeler V; Cheng Z; Berndorff D; Gambhir SS
    Clin Cancer Res; 2015 Jan; 21(2):335-46. PubMed ID: 25381339
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of FAZA PET hypoxia and HPV-status for the outcome of head and neck squamous cell carcinoma (HNSCC) treated with radiotherapy: Long-term results from the DAHANCA 24 trial (NCT01017224).
    Saksø M; Mortensen LS; Primdahl H; Johansen J; Kallehauge J; Hansen CR; Overgaard J
    Radiother Oncol; 2020 Oct; 151():126-133. PubMed ID: 32805273
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacologically increased tumor hypoxia can be measured by 18F-Fluoroazomycin arabinoside positron emission tomography and enhances tumor response to hypoxic cytotoxin PR-104.
    Cairns RA; Bennewith KL; Graves EE; Giaccia AJ; Chang DT; Denko NC
    Clin Cancer Res; 2009 Dec; 15(23):7170-4. PubMed ID: 19920111
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 18F-EF5 PET imaging as an early response biomarker for the hypoxia-activated prodrug SN30000 combined with radiation treatment in a non-small cell lung cancer xenograft model.
    Chitneni SK; Bida GT; Yuan H; Palmer GM; Hay MP; Melcher T; Wilson WR; Zalutsky MR; Dewhirst MW
    J Nucl Med; 2013 Aug; 54(8):1339-46. PubMed ID: 23740105
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Initial results of hypoxia imaging using 1-alpha-D: -(5-deoxy-5-[18F]-fluoroarabinofuranosyl)-2-nitroimidazole ( 18F-FAZA).
    Postema EJ; McEwan AJ; Riauka TA; Kumar P; Richmond DA; Abrams DN; Wiebe LI
    Eur J Nucl Med Mol Imaging; 2009 Oct; 36(10):1565-73. PubMed ID: 19430784
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multiparametric Analysis of the Relationship Between Tumor Hypoxia and Perfusion with ¹⁸F-Fluoroazomycin Arabinoside and ¹⁵O-H₂O PET.
    Iqbal R; Kramer GM; Verwer EE; Huisman MC; de Langen AJ; Bahce I; van Velden FH; Windhorst AD; Lammertsma AA; Hoekstra OS; Boellaard R
    J Nucl Med; 2016 Apr; 57(4):530-5. PubMed ID: 26659349
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 4-[3-(2-Nitro-1-imidazolyl)propylamino]-7-chloroquinoline hydrochloride (NLCQ-1), a novel bioreductive agent as radiosensitizer in vitro and in vivo: comparison with tirapazamine.
    Papadopoulou MV; Ji M; Rao MK; Bloomer WD
    Oncol Res; 2001; 12(8):325-33. PubMed ID: 11589303
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potential role of hypoxia imaging using (18)F-FAZA PET to guide hypoxia-driven interventions (carbogen breathing or dose escalation) in radiation therapy.
    Tran LB; Bol A; Labar D; Karroum O; Bol V; Jordan B; Grégoire V; Gallez B
    Radiother Oncol; 2014 Nov; 113(2):204-9. PubMed ID: 25434767
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of hypoxic subvolumes in laryngeal cancer with (18)F-fluoroazomycinarabinoside ((18)F-FAZA)-PET/CT scanning and immunohistochemistry.
    Bruine de Bruin L; Bollineni VR; Wachters JE; Schuuring E; van Hemel BM; van der Wal JE; Slagter-Menkema L; de Bock GH; Steenbakkers RJ; Langendijk JA; Pruim J; van der Laan BF; Halmos GB
    Radiother Oncol; 2015 Oct; 117(1):106-12. PubMed ID: 26250803
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanism-Specific Pharmacodynamics of a Novel Complex-I Inhibitor Quantified by Imaging Reversal of Consumptive Hypoxia with [
    Gammon ST; Pisaneschi F; Bandi ML; Smith MG; Sun Y; Rao Y; Muller F; Wong F; De Groot J; Ackroyd J; Mawlawi O; Davies MA; Gopal YNV; Di Francesco ME; Marszalek JR; Dewhirst M; Piwnica-Worms D
    Cells; 2019 Nov; 8(12):. PubMed ID: 31766580
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    Metser U; Kohan A; O'Brien C; Wong RKS; Ortega C; Veit-Haibach P; Driscoll B; Yeung I; Farag A
    Tomography; 2024 Aug; 10(9):1354-1364. PubMed ID: 39330748
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhancing targeted radiotherapy by copper(II)diacetyl- bis(N4-methylthiosemicarbazone) using 2-deoxy-D-glucose.
    Aft RL; Lewis JS; Zhang F; Kim J; Welch MJ
    Cancer Res; 2003 Sep; 63(17):5496-504. PubMed ID: 14500386
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.